Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "OncLive" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about OncLive for you to read. Along with our medical data and news we also list OncLive Clinical Trials, which are updated daily. BioPortfolio also has a large database of OncLive Companies for you to search.
The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.
Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.
Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.
Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.
The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.
Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.
Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.
Ropotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.
Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.
The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.
The FDA has lifted a partial clinical hold on tazemetostat trials, reopening enrollment to clinical studies examining the EZH2 inhibitor in patients with various solid tumors and hematologic malignancies.
Kendra Sweet, MD, sheds light on data regarding treatment discontinuation and how they impact patients with chronic myeloid leukemia.
Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.
Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.
A National Center for Health Statistics briefing showed that liver cancer death rates increased significantly for both sexes, with death rates for men 2 to 2.5 times the rate for women from 2000 through 2016.
The European Medicines Agency’s Committee for Medicinal Products for Human Use is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of filgrastim-sndz, a biosimilar for pegfilgrastim.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended full approval of brigatinib (Alunbrig) as a treatment for patients with advanced ALK-positive non–small cell lung cancer who are previously treated with crizotinib (Xalkori).
Heather Wakelee, MD, shares insight on emerging treatment strategies in EGFR–positive non–small cell lung cancer.
The Japanese Ministry of Health, Labor, and Welfare has approved abemaciclib (Verzenio) for the treatment of patients with HR-positive, HER2-negative unresectable or recurrent breast cancer in combination with fulvestrant (Faslodex) or an aromatase inhibitor.
Jubilee Brown, MD, Brown explains the value of genetic testing for patients predisposed to and diagnosed with ovarian cancer.
Abhinav Deol, MD, discusses the basics of chimeric antigen receptor T-cell therapy, potential new directions for these products, and the possible impact new products might have on the field.
Rebecca Alexandra Dent, MD, MSc, discusses which patients will derive the most benefit with ipatasertib, whether the agent can fill the unmet need for patients with PIK3CA-mutated TNBC, and what she hopes to learn from the results of the ongoing phase III IPATunity130 trial.
Patrick M. Forde, MBBCh, discusses the advances in early-stage non–small cell lung cancer, emphasizing neoadjuvant and adjuvant immunotherapy trials in stage I, II, and III disease.
The European Commission has approved the combination of encorafenib (Braftovi) and binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.